High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment
暂无分享,去创建一个
Joan Palou | A. Breda | J. Palou | Alberto Breda | Oscar Rodriguez Faba | H. Villavicencio | H. Villavicencio | Ó. R. Faba
[1] S. Shariat,et al. Accurate preoperative prediction of non‐organ‐confined bladder urothelial carcinoma at cystectomy , 2013, BJU international.
[2] J. McKiernan,et al. Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference? , 2012, BJU international.
[3] M. Cosentino,et al. [A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors]. , 2012, Actas urologicas espanolas.
[4] C. Bayer,et al. Nuclear matrix protein‐22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study , 2012, BJU international.
[5] Jinsung Park,et al. Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor. , 2012, Journal of endourology.
[6] Kerstin Amann,et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer , 2012, BJU international.
[7] R. Sylvester,et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. , 2012, European urology.
[8] Andrea Minervini,et al. A comparison of hexaminolevulinate (Hexvix®) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study , 2012, Surgical Endoscopy.
[9] T. Ørntoft,et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. , 2012, The American journal of pathology.
[10] Sunjay Jain,et al. GOOD QUALITY WHITE‐LIGHT TRANSURETHRAL RESECTION OF BLADDER TUMOURS (GQ‐WLTURBT) WITH EXPERIENCED SURGEONS PERFORMING COMPLETE RESECTIONS AND OBTAINING DETRUSOR MUSCLE REDUCES EARLY RECURRENCE IN NEW NON‐MUSCLE‐INVASIVE BLADDER CANCER: VALIDATION ACROSS TIME AND PLACE AND RECOMMENDATION FOR BENCHMAR , 2012, BJU international.
[11] C. Pan,et al. Prognostic Significance in Substaging of T1 Urinary Bladder Urothelial Carcinoma on Transurethral Resection , 2012, The American journal of surgical pathology.
[12] B. Geavlete,et al. Treatment changes and long‐term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non‐muscle‐invasive bladder cancer (NMIBC)? , 2012, BJU international.
[13] T. H. van der Kwast,et al. A new and highly prognostic system to discern T1 bladder cancer substage. , 2012, European urology.
[14] J. Chin,et al. Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes? , 2012, World Journal of Urology.
[15] A. Vlahou,et al. Profilin 1 is a Potential Biomarker for Bladder Cancer Aggressiveness* , 2011, Molecular & Cellular Proteomics.
[16] Raj Persad,et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. , 2011, The Journal of urology.
[17] L. Martínez-Piñeiro,et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. , 2011, European urology.
[18] J. Witjes,et al. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. , 2011, European urology.
[19] R. Meijer,et al. The risk profiles of three clinical types of carcinoma in situ of the bladder , 2011, BJU international.
[20] J. P. Burgués,et al. Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group , 2011 .
[21] H. Grossman,et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. , 2011, European urology.
[22] J. Burgués,et al. Diagnóstico fotodinámico con hexaminolevulinato en el cáncer vesical no músculo invasivo: experiencia del grupo BLUE , 2011 .
[23] Carsten Wiuf,et al. Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers , 2011, Clinical Cancer Research.
[24] J. Serth,et al. Decreased Galectin-8 Is a Strong Marker for Recurrence in Urothelial Carcinoma of the Bladder , 2011, Urologia Internationalis.
[25] F. Algaba,et al. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. , 2011, European urology.
[26] A. Gross,et al. Tm:YAG laser en bloc mucosectomy for accurate staging of primary bladder cancer: early experience , 2011, World Journal of Urology.
[27] U. Nagele,et al. Waterjet hydrodissection: first experiences and short-term outcomes of a novel approach to bladder tumor resection , 2011, World Journal of Urology.
[28] A. Hartmann,et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer , 2011, BJU international.
[29] A. Hartmann,et al. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. , 2010, American journal of clinical pathology.
[30] Y. Lotan,et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. , 2010, Urologic oncology.
[31] C. Stief,et al. CEACAM1: a novel urinary marker for bladder cancer detection. , 2010, European urology.
[32] Dieter Jocham,et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. , 2010, European urology.
[33] G. Steineck,et al. Diagnostic random bladder biopsies: Reflections from a population-based cohort of 538 patients , 2010, Scandinavian journal of urology and nephrology.
[34] A. Bohle. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer , 2009 .
[35] L. Martínez-Piñeiro,et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.
[36] F. Algaba,et al. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin. , 2009, European urology.
[37] V. Lokeshwar,et al. Potential new urinary markers in the early detection of bladder cancer , 2009, Current opinion in urology.
[38] Y. Lotan,et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. , 2009, The Journal of urology.
[39] Liang Cheng,et al. Staging and reporting of urothelial carcinoma of the urinary bladder , 2009, Modern Pathology.
[40] T. Hajdinjak. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. , 2008, Urologic oncology.
[41] M. Babjuk,et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.
[42] J. Witjes,et al. Urinary markers in bladder cancer. , 2008, European urology.
[43] L. Martínez-Piñeiro,et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. , 2008, European urology.
[44] M. Babjuk,et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. , 2008, Urology.
[45] J. Jones,et al. Defining the role of NMP22 in bladder cancer surveillance , 2008, World Journal of Urology.
[46] M. Raitanen,et al. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies , 2008, World Journal of Urology.
[47] P. Schellhammer,et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.
[48] T. Ebert,et al. Immunocytology in the assessment of patients with asymptomatic microhaematuria. , 2007, European urology.
[49] A. Vickers,et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. , 2007, The Journal of urology.
[50] Y. Lotan,et al. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. , 2006, Urology.
[51] A. Rosales,et al. Re: Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. , 2006, Journal of Urology.
[52] J Alfred Witjes,et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.
[53] H. Woo,et al. Management of stage T1 tumors of the bladder: International Consensus Panel. , 2005, Urology.
[54] H. Herr. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. , 2005, The Journal of urology.
[55] J. Witjes,et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. , 2005, Urology.
[56] Dieter Jocham,et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. , 2005, The Journal of urology.
[57] A. Pycha,et al. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. , 2005, Anticancer research.
[58] A. Orsola,et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. , 2005, European urology.
[59] F. Wiklund,et al. Results of second-look resection after primary resection of T1 tumour of the urinary bladder , 2005, Scandinavian journal of urology and nephrology.
[60] J. Montie. Prognosis of Muscle-Invasive Bladder Cancer: Difference Between Primary and Progressive Tumours and Implications for Therapy , 2005 .
[61] M. Soloway. Re: Schrier BPh, Hollander MP, van Rhijn BWG, Kiemeney LALM, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004;45:292-6. , 2005, European urology.
[62] B. Malavaud. T1G3 bladder tumours: the case for radical cystectomy. , 2004, European urology.
[63] M. Soloway,et al. Expectant management of small, recurrent, noninvasive papillary bladder tumors. , 2003, The Journal of urology.
[64] Dieter Jocham,et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. , 2003, The Journal of urology.
[65] L. Martínez-Piñeiro,et al. Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille calmette-guérin with a reduced dose of 27mg in superficial bladder cancer. , 2003 .
[66] D. Lamm,et al. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.
[67] Laurence Collette,et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. , 2002, European urology.
[68] J. L. Sebastian,et al. Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer , 2002, BJU international.
[69] H. Habermann,et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? , 2002, Urology.
[70] O. Bouchot,et al. [T1 bladder tumors: value of a second endoscopic resection]. , 2002, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[71] H. Ozen,et al. Repeated transurethral resection and intravesical BCG for extensive superficial bladder tumors. , 2001, Journal of endourology.
[72] F. Algaba,et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. , 2000, The Journal of urology.
[73] D. Lamm,et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.
[74] A. Hartmann,et al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. , 2014, European urology.
[75] M. Babjuk,et al. [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. , 2012, Actas urologicas espanolas.
[76] G. Mowatt,et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. , 2010, Health technology assessment.
[77] J. Gschwend,et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. , 2010, European urology.
[78] J. Huguet,et al. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy]. , 2010, Actas urologicas espanolas.
[79] J. Huguet,et al. Cistectomía radical en tumores vesicales no músculo-infiltrantes que fracasan al tratamiento con bacilo de Calmette-Guérin , 2010 .